Back to Journals » Oncolytic Virotherapy » Volume 4

On the potential of oncolytic virotherapy for the treatment of canine cancers

Authors MacNeill AL

Received 16 May 2015

Accepted for publication 29 June 2015

Published 26 August 2015 Volume 2015:4 Pages 95—107

DOI https://doi.org/10.2147/OV.S66358

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Malathi Krishnamurthy

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Amy L MacNeill

Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA

Abstract: Over 6 million dogs are diagnosed with cancer in the USA each year. Treatment options for many of these patients are limited. It is important that the veterinary and scientific communities begin to explore novel treatment protocols for dogs with cancer. Oncolytic viral therapy is a promising treatment option that may prove to be relatively inexpensive and effective against several types of cancer. The efficacy of oncolytic virus therapies has been clearly demonstrated in murine cancer models, but the positive outcomes observed in mice are not always seen in human cancer patients. These therapies should be thoroughly evaluated in dogs with spontaneously arising cancers to provide needed information about the potential effectiveness of virus treatment for human cancers and to promote the health of our companion animals. This article provides a review of the results of oncolytic virus treatment of canine cancers.

Keywords: oncolytic virus, cancer, canine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]